Takeda said more than half of plaque psoriasis patients treated with zasocitinib achieved clear or almost clear skin in two Phase 3 studies. Regulatory submissions for the TYK2 inhibitor are planned for 2026 and clinical trials are ongoing in other indications. The post Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Congress’s failure to renew the ACA’s enhanced premium tax credits risks creating a healthcare crisis for millions
“We’re done with junk science,” RFK Jr. said in a news conference on Thursday
CMS’ new ACCESS model, slated to begin on July 1, aims to shift traditional Medicare fee-for-service toward value-based care by tying payments to patient outcomes and encouraging tech-enabled, preventive care. Experts say it could benefit digitally mature, value-focused providers first, but its overall success will hinge on clear metrics, better data sharing and sustained participation….
Funding cuts to the AAP include programs on infant mortality, adolescent health, and autism detection
This brief provides an overview of the role of PBMs in managing pharmacy benefits, discusses recent federal legislation focusing on several elements of PBM business practices, and explains the potential federal budgetary impact of this legislation, which would have a relatively modest impact on the federal deficit, based on available CBO estimates.
First area of focus for Allina’s new R&D team is specialty referrals, says COO Dominica Tallarico
Polysight launches its platform with a pilot at 11-hospital Wellstar Health System
With new therapies being approved, and many others in the pipeline, they raise a critical question: Is our healthcare system prepared to deliver them effectively and sustainably? The post Breakthrough Therapies Aren’t Enough: What Neurology Needs Now appeared first on MedCity News.